Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Displaying drugs 601 - 625 of 1990 in total

Oxaliplatin

Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. Compared to cisplatin the two amine groups are replaced by diamino cyclohexane (DACH) group to provide a greater antitumor effect. However, this leads to poorer water solubility, which was compensated by the addition of the chloride...
Approved
Investigational
Matched Description: … refractory to an initial fluorouracil and leucovorin combination. ... Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. ... [A260396] The DACH moiety also prevents cross-resistance with cisplatin and carboplatin. …
Matched Categories: … Antineoplastic and Immunomodulating Agents …

Fosphenytoin

Fosphenytoin is a water-soluble phenytoin prodrug used only in hospitals for the treatment of epileptic seizures. It works by slowing down impulses in the brain that cause seizures. Its main mechanism is to block frequency-dependent, use-dependent and voltage-dependent neuronal sodium channels, and therefore limit repetitive firing of action potentials.
Approved
Investigational
Matched Description: … channels, and therefore limit repetitive firing of action potentials. ... Its main mechanism is to block frequency-dependent, use-dependent and voltage-dependent neuronal sodium …
Matched Categories: … Phenytoin and Prodrugs …

Lutetium Lu-177 vipivotide tetraxetan

Lutetium Lu-177 vipivotide tetraxetan is a radioligand therapeutic agent. It consists of a radionuclide, lutetium Lu-177, linked to a moiety that binds to PSMA, a transmembrane protein that is expressed in prostate cancer. Lutetium Lu-177 vipivotide tetraxetan was first approved by the FDA on March 23, 2022 as a treatment...
Approved
Matched Description: … [L41290] In October 2022, the EMA's Committee for Medicinal Products for Human Use (CHMP) recommended …

Saquinavir

Saquinavir is an HIV-1 protease inhibitor used in combination with ritonavir and other antiretrovirals for the treatment of human immunodeficiency virus-1 (HIV-1) infection. In 1995 it became the first protease inhibitor approved by the FDA, followed shortly by ritonavir in 1996, and remains in clinical use today due to a...
Approved
Investigational
Matched Description: … for the treatment of human immunodeficiency virus-1 (HIV-1) infection. ... Saquinavir is an HIV-1 protease inhibitor used in combination with [ritonavir] and other antiretrovirals ... it became the first protease inhibitor approved by the FDA, followed shortly by ritonavir in 1996, and …
Matched Categories: … Metabolic Side Effects of Drugs and Substances …

Zolpidem

Zolpidem, also known as Ambien, is a hypnotic drug that was initially approved by the FDA in 1992 [FDA label]. Zolpidem improves sleep in patients with insomnia. It is aimed for use in patients with difficulties initiating sleep. This drug decreases the time to fall asleep (sleep latency), increases the...
Approved
Matched Description: … It is available in both immediate acting and extended release forms [FDA label], [F3802]. ... In addition, zolpidem improves sleep quality in patients suffering from chronic insomnia and can show ... Research also shows that zolpidem is rapid and effective in restoring brain function for patients in …
Matched Categories: … Hypnotics and Sedatives ... Benzodiazepine hypnotics and sedatives ... Miscellaneous Anxiolytics Sedatives and Hypnotics …

Hydroxyurea

Hydroxyurea is a non-alkylating antineoplastic agent that was first synthesized in 1869 but was not characterized biologically until 1928. It was first approved by the FDA in 1998 for the treatment of sickle cell anemia in adults. Although clinical evidence on the efficacy of hydroxyurea in certain conditions exists, hydroxyurea...
Approved
Matched Description: … adherence, the need for therapeutic monitoring, and serious side effects of secondary cancer and birth ... conditions exists, hydroxyurea is used sparingly in clinical settings, largely due to lack of knowledge and …
Matched Categories: … Antineoplastic and Immunomodulating Agents …

Naloxegol

Naloxegol, for "PEGylated naloxol" is a peripherally-selective opioid antagonist developed by AstraZeneca. It was approved by the FDA in September 2014 and is indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non‑cancer pain. The advantage of naloxegol over the opioid antagonist naloxone is that its...
Approved
Matched Description: … naloxone is that its PEGylated structure allows for high selectivity for peripheral opioid receptors and ... It was approved by the FDA in September 2014 and is indicated for the treatment of opioid-induced constipation …
Matched Categories: … Alimentary Tract and Metabolism …

Fosfomycin

Fosfomycin was discovered in 1969 by scientists at the Spanish Penicillin and Antibiotics Company and is produced by Streptomyces fradiae.[A229338,A230348] It may also be produced synthetically and is commercially available as the disodium salt for intravenous administration and as the calcium or trometamol salt for oral administration. In terms of...
Approved
Matched Description: … group and an epoxide ring. ... Fosfomycin was discovered in 1969 by scientists at the Spanish Penicillin and Antibiotics Company and ... is active against both gram-positive and gram-negative bacteria. …

Azilsartan medoxomil

Azilsartan medoxomil is a prodrug that is broken down to azilsartan, which belongs in the angiotensin-receptor blocking (ARB) drug class. It is a selective AT1 subtype angiotensin II receptor antagonist. Azilsartan medoxomil is a relatively recently-developed antihypertensive drug that was first approved by the FDA in February 2011. Many guidelines...
Approved
Investigational
Matched Description: … , primarily strokes and myocardial infarctions. ... guidelines recommend the use of ARBs as first-line therapy when initiating antihypertensive therapy and ... Lowering blood pressure is associated with a reduced risk of fatal and nonfatal cardiovascular events …
Matched Categories: … azilsartan medoxomil and diuretics ... Angiotensin II receptor blockers (ARBs) and diuretics …

Inulin

A starch found in the tubers and roots of many plants. Since it is hydrolyzable to fructose, it is classified as a fructosan. It has been used in physiologic investigation for determination of the rate of glomerular function.
Approved
Investigational
Nutraceutical
Matched Description: … A starch found in the tubers and roots of many plants. …
Matched Categories: … inulin and other polyfructosans ... Tests for Renal Function and Ureteral Injuries …

Andusomeran

Andusomeran is a COVID-19 mRNA vaccine developed for use during the 2023-2024 season.[L40074,L48832,L48837] It is similar to previous mRNA vaccines developed by Moderna (e.g. elasomeran, imelasomeran), but is designed to be effective against the Omicron XBB.1.5 subvariant.
Approved

Silodosin

Silodosin is a selective antagonist of alpha(α)-1 adrenergic receptors that binds to the α1A subtype with the highest affinity. α1-adrenergic receptors regulate smooth muscle tone in the bladder neck, prostate, and prostatic urethra: the α1A subtype accounts for approximately 75% of α1-adrenoceptors in the prostate. Silodosin was first approved by...
Approved
Matched Description: … in Europe and Canada. ... Silodosin is available as oral capsules with common trade names Rapaflo and Urorec. ... highest affinity. α1-adrenergic receptors regulate smooth muscle tone in the bladder neck, prostate, and …
Matched Categories: … Genito Urinary System and Sex Hormones …

Repotrectinib

Repotrectinib is a next-generation tyrosine kinase inhibitor (TKI) specifically designed to address resistance in the treatment of non-small cell lung cancer (NSCLC), specifically due to mutations in the ROS1 gene. ROS1 mutations are one of the defined oncogenic drives of NSCLC, and the solvent-front mutation ROS1 G2032R is responsible for...
Approved
Investigational
Matched Description: … [A262056] ROS1 mutations are one of the defined oncogenic drives of NSCLC, and the solvent-front mutation ... compact macrocyclic structure that both limits adverse interactions with resistance mutation hotspots and ... resistance to multiple TKI has been reported, including [crizotinib], [lorlatinib], [taletrectinib], and …

Fosnetupitant

In April 2018, the U.S. Food and Drug Administration (FDA) and the Swiss company Helsinn approved the intravenous formulation of AKYNZEO® (NEPA, a fixed antiemetic combination of fosnetupitant, 235mg, and palonosetron, 0.25mg) as an alternative treatment option for patients experiencing chemotherapy-induced nausea and vomiting . Fosnetupitant is the pro-drug form...
Approved
Matched Description: … Food and Drug Administration (FDA) and the Swiss company Helsinn approved the intravenous formulation ... of AKYNZEO® (NEPA, a fixed antiemetic combination of fosnetupitant, 235mg, and palonosetron, 0.25mg) ... as an alternative treatment option for patients experiencing chemotherapy-induced nausea and vomiting …
Matched Categories: … Netupitant and prodrug …

Palbociclib

Palbociclib is a piperazine pyridopyrimidine that acts in the cell cycle machinery. It is a second generation cyclin-dependent kinase inhibitor selected from a group of pyridopyrimidine compounds due to its favorable physical and pharmaceutical properties. Palbociclib was developed by Pfizer Inc after the discovery that identified the cyclin-dependent kinases as...
Approved
Investigational
Matched Description: … electronic health records demonstrating safety and clinical efficacy. ... inhibitor[A176798] selected from a group of pyridopyrimidine compounds due to its favorable physical and ... on March 2015 for the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer and …
Matched Categories: … Antineoplastic and Immunomodulating Agents …

Selenomethionine

Selenomethionine is a naturally occuring amino acid in some plant materials such as cereal grains, soybeans and enriched yeast but it cannot be synthesized from animals or humans. It can be produced from post-structural modifications. In vivo, selenomethionine plays an essential role in acting as an antioxidant, where it depletes...
Approved
Investigational
Matched Description: … the inorganic form of selenium, the organic form of selenomethionine is more readily absorbed in the human ... aids in the formation and recycling of glutathione, another important antioxidant. ... Selenomethionine is a naturally occuring amino acid in some plant materials such as cereal grains, soybeans and …
Matched Categories: … Amino Acids, Peptides, and Proteins …

Peramivir

Peramivir is an antiviral agent developed by Biocryst Pharmaceuticals to treat influenza A/B. The development of peramivir has been supported by the US Department of Health and Human Services as part of the government's effort to prepare for a flu pandemic. Being an influenza virus neuraminidase inhibitor, peramivir works by...
Approved
Investigational
Matched Description: … The development of peramivir has been supported by the US Department of Health and Human Services as ... the poor oral bioavailability, the oral formulation of the drug was previously abandoned by Johnson and ... in September 2017 for the treatment of acute uncomplicated influenza to pediatric patients 2 years and …

Ecallantide

Ecallantide is a potent and selective human plasma kallikrein inhibitor that is indicated for the symptomatic treatment of hereditary angioedema. Ecallantide is a recombinant 60-amino-acid protein produced in Pichia pastoris yeast cells that contains three intramolecular disulfide bonds [FDA Label]. It was discovered by phage display technology . It shares...
Approved
Investigational
Matched Description: … Ecallantide is a potent and selective human plasma kallikrein inhibitor that is indicated for the symptomatic ... It shares sequence similarities with the naturally occurring human protein tissue-factor pathway inhibitor ... activity of kallikrein and excessive bradykinin production [FDA Label]. …
Matched Categories: … Blood and Blood Forming Organs ... Amino Acids, Peptides, and Proteins …

Pirtobrutinib

Pirtobrutinib is a small molecule and a highly selective non-covalent inhibitor of Bruton’s tyrosine kinase (BTK). Its high selectivity has been associated with lower discontinuation rates due to adverse events and a lower incidence of atrial fibrillation. Unlike BTK covalent inhibitors, such as ibrutinib, that bind to the cysteine 481...
Approved
Investigational
Matched Description: … Pirtobrutinib is a small molecule and a highly selective non-covalent inhibitor of Bruton’s tyrosine ... Its high selectivity has been associated with lower discontinuation rates due to adverse events and a …
Matched Categories: … Antineoplastic and Immunomodulating Agents …

Pilocarpine

A naturally occurring alkaloid derived from the Pilocarpus plants, pilocarpine is a muscarinic acetylcholine agonist.[A262016, A262036] Pilocarpine is associated with parasympathomimetic effects by selectively working on muscarinic receptors. Pilocarpine is used to treat dry mouth and various ophthalmic conditions, including elevated intraocular pressure and glaucoma. The usage of glaucoma by...
Approved
Investigational
Matched Description: … intraocular pressure and glaucoma. ... [A262036] Pilocarpine is used to treat dry mouth and various ophthalmic conditions, including elevated …
Matched Categories: … Antiglaucoma Preparations and Miotics …

Ifosfamide

Ifosfamide is a chemotherapeutic agent chemically related to the nitrogen mustards and a synthetic analog of cyclophosphamide. It is active as an alkylating agent and an immunosuppressive agent.
Approved
Matched Description: … It is active as an alkylating agent and an immunosuppressive agent. ... Ifosfamide is a chemotherapeutic agent chemically related to the nitrogen mustards and a synthetic analog …
Matched Mixtures name: … IFEX and MESNEX ... IFEX and MESNEX ... IFEX and MESNEX …
Matched Categories: … Antineoplastic and Immunomodulating Agents …

Glasdegib

Glasdegib, also known as PF-04449913, is a small-molecule hedgehog signaling inhibitor selected under the group of benzimidazoles. In early research, benzimidazoles attracted large interest as they represented a class of inhibitors with low molecular weight, potent inhibitory activity, and lacking unstable functionality. The great lipophilicity of this group of compounds...
Approved
Investigational
Matched Description: … [A40310] Glasdegib was developed by Pfizer Inc and approved on November 21, 2018 by the FDA for the ... interest as they represented a class of inhibitors with low molecular weight, potent inhibitory activity, and ... monotherapy is limited, the landmark Phase 2 Bright AML 1003 trial showed a superior overall survival and …
Matched Categories: … Antineoplastic and Immunomodulating Agents …

Tretinoin

Tretinoin, also known as all-trans-retinoic acid (ATRA), is a naturally occurring derivative of vitamin A (retinol). It is an oxidation product in the physiological pathway of vitamin A metabolism. In human circulation, tretinoin is normally found at very low concentrations, approximately 4 to 14 nmol/L. Tretinoin exhibits anti-inflammatory, antineoplastic, antioxidant,...
Approved
Investigational
Nutraceutical
Matched Description: … [A257689] In human circulation, tretinoin is normally found at very low concentrations, approximately ... activates nuclear receptors to regulate epithelial cell growth and differentiation. ... [A257689] Tretinoin exhibits anti-inflammatory, antineoplastic, antioxidant, and free radical-scavenging …
Matched Mixtures name: … Clindamycin Phosphate and Tretinion ... OLIVIA QUIDO FIRM and FADE I ... OLIVIA QUIDO FIRM and FADE II …
Matched Categories: … Cell Stimulants and Proliferants ... Antineoplastic and Immunomodulating Agents …

Risedronic acid

Risedronic acid is a third generation bisphosphonate that is used for the treatment of some forms of osteoperosis and Paget's disease[FDA Label][A959,A203111]. It functions by preventing resorption of bone[FDA Label] .
Approved
Investigational
Matched Description: … acid is a third generation bisphosphonate that is used for the treatment of some forms of osteoperosis and …
Matched Categories: … Calcium-Regulating Hormones and Agents ... risedronic acid and colecalciferol ... risedronic acid and calcium, sequential ... Drugs Affecting Bone Structure and Mineralization ... risedronic acid, calcium and colecalciferol, sequential …

Anastrozole

Anastrozole is a non-steroidal aromatase inhibitor (AI), similar to letrozole, used to decrease circulating estrogen levels in the treatment of postmenopausal women with estrogen-responsive breast cancer. Anastrozole is also related to exemestane, a steroidal AI, but its non-steroidal nature provides stark advantages including a lack of steroid-associated adverse effects such...
Approved
Investigational
Matched Description: … provides stark advantages including a lack of steroid-associated adverse effects such as weight gain and ... drugs of choice in the treatment of postmenopausal breast cancer due to a more favourable efficacy and …
Matched Categories: … Antineoplastic and Immunomodulating Agents ... Hormone Antagonists and Related Agents ... Hormones, Hormone Substitutes, and Hormone Antagonists …
Displaying drugs 601 - 625 of 1990 in total